Intercept upgraded to Buy from Neutral by Citi

Target to $85 from $106

https://www.benzinga.com/stock/ICPT/ratings

Emergent BioSolutions upped to Outperform by Wells Fargo

From Market Perform; target to $64 from $61

https://www.benzinga.com/stock/EBS/ratings

Castle Biosciences target upped to $34 from $26 by Canaccord

Maintains Buy

https://www.benzinga.com/stock/CSTL/ratings

Concert Pharma target raised to $29 from $23 by Mizuho

Maintains Buy

https://www.benzinga.com/stock/CNCE/ratings

BioLife Solutions target upped to $22 from $18 by Northland

Maintains Outperform

https://www.benzinga.com/stock/BLFS/ratings

Atreca started at Buy by Roth

Target $30

https://www.benzinga.com/stock/BCEI/ratings

Allergan: FDA OKs Juvederm VOLUMA XC for Mid-Face Injection via Cannula

Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvederm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21.

A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvederm VOLUMA XC in the cheek area. The TSK STERiGLIDE has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.

https://www.marketscreener.com/ALLERGAN-PLC-22497284/news/Allergan-Receives-FDA-Approval-of-Juvederm-VOLUMA-XC-for-Mid-Face-Injection-via-Cannula-29157804/